Medtronic Rewards Shareholders with 49th Dividend Hike While Expanding Neurovascular Reach
17.06.2026 - 01:11:50 | boerse-global.de
The medical technology giant is walking two parallel paths — returning capital to shareholders and investing in future growth — as it closes a transformative year. Medtronic posted its strongest organic revenue growth in a decade, hitting $36.3 billion for the fiscal year, up nearly 6 percent organically. At the same time, the company sealed a $550 million acquisition of Scientia Vascular, a private developer of guidewires and catheters designed for complex neurological procedures.
Free cash flow climbed to $5.4 billion, the highest level in four years, providing ample firepower for both the dividend increase and the bolt-on deal. Adjusted earnings per share for the fourth quarter came in at $1.55, beating the company’s own internal forecast.
Cardiovascular segment drives the quarter
A standout performer was the cardiovascular business, where fourth-quarter revenue jumped almost 14 percent. Within that division, cardiac ablation solutions globally surged 78 percent, and on the U.S. market the segment more than doubled. That momentum underpinned the management’s decision to raise the quarterly dividend to $0.72 per share, marking the 49th consecutive annual increase — a streak that cements Medtronic’s status among dividend aristocrats. The payout is scheduled for July 17 to shareholders of record.
Should investors sell immediately? Or is it worth buying Medtronic?
Scientia Vascular plugs into neurovascular portfolio
The Scientia acquisition bolsters Medtronic’s existing neurovascular business with specialized tools for navigating intricate brain anatomy during stroke and aneurysm interventions. Linnea Burman, head of the neurovascular unit, described the deal as creating an integrated platform to improve patient care. In addition to the upfront $550 million, Medtronic may owe undisclosed milestone payments.
From a financial perspective, the deal is expected to be slightly dilutive to adjusted earnings per share in fiscal 2027, turning accretive the following year. Integration speed and the ability to drive measurable growth in the neurovascular segment will be key when Medtronic reports its next quarterly results.
Stock lags operating performance
Despite the strong operational numbers, the share price has not kept pace. Medtronic shares trade around €70, having slipped roughly 15 percent since the start of the year. That puts the stock about 11 percent above its 2024 low from early June, but still well below its 200-day moving average of €79.09. The recent modest recovery above the 50-day line offers some technical comfort, but the broader trend remains under pressure.
For the new fiscal year, management is targeting organic revenue growth of about 7 percent and adjusted earnings per share of up to $6.00. The solid fourth-quarter results provide a foundation for that guidance, but the market is waiting to see whether the Scientia integration and continued momentum in cardiovascular can close the valuation gap.
Ad
Medtronic Stock: New Analysis - 17 June
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
